Which has stronger valuation and earnings, IRON or AURA?

Disc Medicine is trading at a lower price-to-earnings ratio than Aura Biosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Disc Medicine N/A N/A -$212.18M -$6.58 N/A Aura Biosciences N/A N/A -$106.19M -$1.75 N/A

Is IRON or AURA more profitable?

Disc Medicine's return on equity of -37.17% beat Aura Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Disc Medicine N/A -37.17% -33.65% Aura Biosciences N/A -73.18% -62.00%

Which has higher earnings & valuation, AURA or IMNM?

Immunome is trading at a lower price-to-earnings ratio than Aura Biosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aura Biosciences N/A N/A -$106.19M -$1.75 N/A Immunome N/A N/A -$212.39M -$2.53 N/A

Is AURA or IMNM more profitable?

Immunome's return on equity of -50.56% beat Aura Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Aura Biosciences N/A -73.18% -62.00% Immunome N/A -50.56% -46.93%

Is CLDX or AURA more profitable?

Celldex Therapeutics' return on equity of -52.35% beat Aura Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Celldex Therapeutics N/A -52.35% -47.61% Aura Biosciences N/A -73.18% -62.00%

Aura Biosciences (AURA) Competitors

$6.09 +0.05 (+0.83%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$6.19 +0.10 (+1.66%)

As of 10/2/2026 07:30 PM Eastern

Compare

AURA vs. BEAM, IRON, IMNM, CLDX, and NRIX

Should you buy Aura Biosciences stock or one of its competitors? Aura Biosciences's main competitors and comparable companies include Beam Therapeutics (BEAM), Disc Medicine (IRON), Immunome (IMNM), Celldex Therapeutics (CLDX), and Nurix Therapeutics (NRIX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Aura Biosciences compare to Beam Therapeutics?

Aura Biosciences (NASDAQ:AURA) and Beam Therapeutics (NASDAQ:BEAM) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, media sentiment, dividends and valuation.

Aura Biosciences has a net margin of 0.00% compared to Beam Therapeutics' net margin of -54.75%. Beam Therapeutics' return on equity of -30.71% beat Aura Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aura Biosciences	N/A	-73.18%	-62.00%
Beam Therapeutics	-54.75%	-30.71%	-24.07%

Aura Biosciences has a beta of 0.41, suggesting that its stock price is 59% less volatile than the broader market. Comparatively, Beam Therapeutics has a beta of 2.2, suggesting that its stock price is 120% more volatile than the broader market.

Aura Biosciences presently has a consensus target price of $17.50, suggesting a potential upside of 187.36%. Beam Therapeutics has a consensus target price of $49.00, suggesting a potential upside of 100.00%. Given Aura Biosciences' higher probable upside, equities research analysts plainly believe Aura Biosciences is more favorable than Beam Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aura Biosciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Beam Therapeutics	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.79

Beam Therapeutics has higher revenue and earnings than Aura Biosciences. Beam Therapeutics is trading at a lower price-to-earnings ratio than Aura Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aura Biosciences	N/A	N/A	-$106.19M	-$1.75	N/A
Beam Therapeutics	$156.04M	16.22	-$79.99M	-$0.86	N/A

In the previous week, Beam Therapeutics had 8 more articles in the media than Aura Biosciences. MarketBeat recorded 8 mentions for Beam Therapeutics and 0 mentions for Aura Biosciences. Beam Therapeutics' average media sentiment score of 0.33 beat Aura Biosciences' score of 0.00 indicating that Beam Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Aura Biosciences	Neutral
Beam Therapeutics	Neutral

96.8% of Aura Biosciences shares are owned by institutional investors. Comparatively, 99.7% of Beam Therapeutics shares are owned by institutional investors. 1.9% of Aura Biosciences shares are owned by insiders. Comparatively, 3.8% of Beam Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Beam Therapeutics beats Aura Biosciences on 13 of the 16 factors compared between the two stocks.

How does Aura Biosciences compare to Disc Medicine?

Disc Medicine (NASDAQ:IRON) and Aura Biosciences (NASDAQ:AURA) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, media sentiment, institutional ownership, risk, dividends, valuation and earnings.

83.7% of Disc Medicine shares are owned by institutional investors. Comparatively, 96.8% of Aura Biosciences shares are owned by institutional investors. 3.8% of Disc Medicine shares are owned by insiders. Comparatively, 1.9% of Aura Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Disc Medicine had 5 more articles in the media than Aura Biosciences. MarketBeat recorded 5 mentions for Disc Medicine and 0 mentions for Aura Biosciences. Disc Medicine's average media sentiment score of 0.41 beat Aura Biosciences' score of 0.00 indicating that Disc Medicine is being referred to more favorably in the media.

Company	Overall Sentiment
Disc Medicine	Neutral
Aura Biosciences	Neutral

Disc Medicine is trading at a lower price-to-earnings ratio than Aura Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Disc Medicine	N/A	N/A	-$212.18M	-$6.58	N/A
Aura Biosciences	N/A	N/A	-$106.19M	-$1.75	N/A

Disc Medicine has a beta of 0.93, indicating that its stock price is 7% less volatile than the broader market. Comparatively, Aura Biosciences has a beta of 0.41, indicating that its stock price is 59% less volatile than the broader market.

Disc Medicine's return on equity of -37.17% beat Aura Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Disc Medicine	N/A	-37.17%	-33.65%
Aura Biosciences	N/A	-73.18%	-62.00%

Disc Medicine currently has a consensus target price of $110.18, suggesting a potential upside of 70.80%. Aura Biosciences has a consensus target price of $17.50, suggesting a potential upside of 187.36%. Given Aura Biosciences' higher probable upside, analysts plainly believe Aura Biosciences is more favorable than Disc Medicine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Disc Medicine	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.77
Aura Biosciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

Disc Medicine beats Aura Biosciences on 8 of the 13 factors compared between the two stocks.

How does Aura Biosciences compare to Immunome?

Aura Biosciences (NASDAQ:AURA) and Immunome (NASDAQ:IMNM) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, media sentiment, dividends, profitability, valuation and earnings.

Immunome is trading at a lower price-to-earnings ratio than Aura Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aura Biosciences	N/A	N/A	-$106.19M	-$1.75	N/A
Immunome	N/A	N/A	-$212.39M	-$2.53	N/A

In the previous week, Immunome had 8 more articles in the media than Aura Biosciences. MarketBeat recorded 8 mentions for Immunome and 0 mentions for Aura Biosciences. Immunome's average media sentiment score of 0.64 beat Aura Biosciences' score of 0.00 indicating that Immunome is being referred to more favorably in the news media.

Company	Overall Sentiment
Aura Biosciences	Neutral
Immunome	Positive

96.8% of Aura Biosciences shares are owned by institutional investors. Comparatively, 44.6% of Immunome shares are owned by institutional investors. 1.9% of Aura Biosciences shares are owned by insiders. Comparatively, 7.2% of Immunome shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Aura Biosciences has a beta of 0.41, indicating that its stock price is 59% less volatile than the broader market. Comparatively, Immunome has a beta of 2.55, indicating that its stock price is 155% more volatile than the broader market.

Aura Biosciences presently has a consensus target price of $17.50, suggesting a potential upside of 187.36%. Immunome has a consensus target price of $34.25, suggesting a potential upside of 63.88%. Given Aura Biosciences' higher probable upside, equities analysts plainly believe Aura Biosciences is more favorable than Immunome.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aura Biosciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Immunome	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.79

Immunome's return on equity of -50.56% beat Aura Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aura Biosciences	N/A	-73.18%	-62.00%
Immunome	N/A	-50.56%	-46.93%

Summary

Immunome beats Aura Biosciences on 8 of the 13 factors compared between the two stocks.

How does Aura Biosciences compare to Celldex Therapeutics?

Celldex Therapeutics (NASDAQ:CLDX) and Aura Biosciences (NASDAQ:AURA) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, valuation, institutional ownership, earnings, profitability, risk, analyst recommendations and dividends.

Aura Biosciences has lower revenue, but higher earnings than Celldex Therapeutics. Celldex Therapeutics is trading at a lower price-to-earnings ratio than Aura Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Celldex Therapeutics	$1.54M	1,613.94	-$258.76M	-$4.35	N/A
Aura Biosciences	N/A	N/A	-$106.19M	-$1.75	N/A

Celldex Therapeutics' return on equity of -52.35% beat Aura Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Celldex Therapeutics	N/A	-52.35%	-47.61%
Aura Biosciences	N/A	-73.18%	-62.00%

Celldex Therapeutics presently has a consensus price target of $61.92, indicating a potential upside of 95.65%. Aura Biosciences has a consensus price target of $17.50, indicating a potential upside of 187.36%. Given Aura Biosciences' higher possible upside, analysts clearly believe Aura Biosciences is more favorable than Celldex Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Celldex Therapeutics	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.86
Aura Biosciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

96.8% of Aura Biosciences shares are owned by institutional investors. 5.2% of Celldex Therapeutics shares are owned by insiders. Comparatively, 1.9% of Aura Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Celldex Therapeutics has a beta of 0.9, indicating that its stock price is 10% less volatile than the broader market. Comparatively, Aura Biosciences has a beta of 0.41, indicating that its stock price is 59% less volatile than the broader market.

In the previous week, Celldex Therapeutics had 3 more articles in the media than Aura Biosciences. MarketBeat recorded 3 mentions for Celldex Therapeutics and 0 mentions for Aura Biosciences. Celldex Therapeutics' average media sentiment score of 0.18 beat Aura Biosciences' score of 0.00 indicating that Celldex Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Celldex Therapeutics	Neutral
Aura Biosciences	Neutral

Summary

Celldex Therapeutics beats Aura Biosciences on 10 of the 15 factors compared between the two stocks.

How does Aura Biosciences compare to Nurix Therapeutics?

Nurix Therapeutics (NASDAQ:NRIX) and Aura Biosciences (NASDAQ:AURA) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, risk, valuation, profitability, media sentiment, institutional ownership and dividends.

Aura Biosciences has lower revenue, but higher earnings than Nurix Therapeutics. Nurix Therapeutics is trading at a lower price-to-earnings ratio than Aura Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nurix Therapeutics	$83.98M	28.41	-$264.46M	-$3.45	N/A
Aura Biosciences	N/A	N/A	-$106.19M	-$1.75	N/A

96.8% of Aura Biosciences shares are owned by institutional investors. 6.7% of Nurix Therapeutics shares are owned by company insiders. Comparatively, 1.9% of Aura Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Nurix Therapeutics has a beta of 1.82, meaning that its stock price is 82% more volatile than the broader market. Comparatively, Aura Biosciences has a beta of 0.41, meaning that its stock price is 59% less volatile than the broader market.

In the previous week, Nurix Therapeutics had 8 more articles in the media than Aura Biosciences. MarketBeat recorded 8 mentions for Nurix Therapeutics and 0 mentions for Aura Biosciences. Nurix Therapeutics' average media sentiment score of 0.29 beat Aura Biosciences' score of 0.00 indicating that Nurix Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Nurix Therapeutics	Neutral
Aura Biosciences	Neutral

Aura Biosciences has a net margin of 0.00% compared to Nurix Therapeutics' net margin of -928.44%. Aura Biosciences' return on equity of -73.18% beat Nurix Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nurix Therapeutics	-928.44%	-76.09%	-57.31%
Aura Biosciences	N/A	-73.18%	-62.00%

Nurix Therapeutics currently has a consensus price target of $34.21, indicating a potential upside of 48.82%. Aura Biosciences has a consensus price target of $17.50, indicating a potential upside of 187.36%. Given Aura Biosciences' higher probable upside, analysts plainly believe Aura Biosciences is more favorable than Nurix Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nurix Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80
Aura Biosciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

Nurix Therapeutics beats Aura Biosciences on 8 of the 15 factors compared between the two stocks.

Get Aura Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AURA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AURA vs. The Competition

Export

Metric	Aura Biosciences	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$626.38M	$3.87B	$7.14B	$13.17B
Dividend Yield	N/A	3.64%	2.53%	16.78%
P/E Ratio	-3.48	13.06	275.68	26.04
Price / Sales	N/A	1,374.07	658.29	101.16
Price / Cash	N/A	122.60	77.60	51.75
Price / Book	2.82	16.63	10.93	6.31
Net Income	-$106.19M	-$22.71M	$3.51B	$362.16M
7 Day Performance	1.50%	-2.99%	-2.00%	-1.66%
1 Month Performance	-17.37%	-10.60%	-6.15%	-4.50%
1 Year Performance	0.66%	19.44%	7.44%	2.06%

Aura Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AURA Aura Biosciences	1.3099 of 5 stars	$6.09 +0.8%	$17.50 +187.4%	+1.2%	$626.38M	N/A	N/A	113	High Trading Volume
BEAM Beam Therapeutics	2.614 of 5 stars	$24.52 +1.2%	$49.00 +99.8%	-4.3%	$2.53B	$139.74M	N/A	540	Analyst Upgrade Gap Up
IRON Disc Medicine	2.5421 of 5 stars	$65.87 +1.5%	$110.18 +67.3%	-2.0%	$2.53B	N/A	N/A	165
IMNM Immunome	2.6551 of 5 stars	$21.89 +1.0%	$35.18 +60.7%	+82.2%	$2.49B	$6.94M	N/A	177	News Coverage Analyst Forecast Gap Up
CLDX Celldex Therapeutics	2.0319 of 5 stars	$31.64 +0.5%	$61.92 +95.7%	+22.4%	$2.48B	$1.54M	N/A	198	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AURA) was last updated on 10/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Aura Biosciences (AURA) Competitors

AURA vs. BEAM, IRON, IMNM, CLDX, and NRIX

How does Aura Biosciences compare to Beam Therapeutics?

Summary

How does Aura Biosciences compare to Disc Medicine?

Summary

How does Aura Biosciences compare to Immunome?

Summary

How does Aura Biosciences compare to Celldex Therapeutics?

Summary

How does Aura Biosciences compare to Nurix Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AURA vs. The Competition

Aura Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Aura Biosciences (AURA) Competitors

AURA vs. BEAM, IRON, IMNM, CLDX, and NRIX

How does Aura Biosciences compare to Beam Therapeutics?

Is AURA or BEAM more profitable?

Which has more risk & volatility, AURA or BEAM?

Do analysts prefer AURA or BEAM?

Which has higher valuation & earnings, AURA or BEAM?

Does the media favor AURA or BEAM?

Do institutionals and insiders have more ownership in AURA or BEAM?

Summary

How does Aura Biosciences compare to Disc Medicine?

Do insiders & institutionals hold more shares of IRON or AURA?

Does the media favor IRON or AURA?

Which has stronger valuation and earnings, IRON or AURA?

Which has more risk & volatility, IRON or AURA?

Is IRON or AURA more profitable?

Do analysts prefer IRON or AURA?

Summary

How does Aura Biosciences compare to Immunome?

Which has higher earnings & valuation, AURA or IMNM?

Does the media favor AURA or IMNM?

Do insiders and institutionals hold more shares of AURA or IMNM?

Which has more risk & volatility, AURA or IMNM?

Do analysts rate AURA or IMNM?

Is AURA or IMNM more profitable?

Summary

How does Aura Biosciences compare to Celldex Therapeutics?

Which has better valuation & earnings, CLDX or AURA?

Is CLDX or AURA more profitable?

Do analysts recommend CLDX or AURA?

Do insiders and institutionals believe in CLDX or AURA?

Which has more volatility & risk, CLDX or AURA?

Does the media prefer CLDX or AURA?

Summary

How does Aura Biosciences compare to Nurix Therapeutics?

Which has better earnings and valuation, NRIX or AURA?

Do institutionals & insiders have more ownership in NRIX or AURA?

Which has more risk and volatility, NRIX or AURA?

Does the media favor NRIX or AURA?

Is NRIX or AURA more profitable?

Do analysts rate NRIX or AURA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AURA vs. The Competition

Aura Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools